Christopoulos Arthur, Kenakin Terry
Department of Pharmacology, University of Melbourne, Parkville, Victoria, Australia.
Pharmacol Rev. 2002 Jun;54(2):323-74. doi: 10.1124/pr.54.2.323.
G protein-coupled receptors (GPCRs) represent the largest family of cell-surface receptors. These receptors are natural allosteric proteins because agonist-mediated signaling by GPCRs requires a conformational change in the receptor protein transmitted between two topographically distinct binding sites, one for the agonist and another for the G protein. It is now becoming increasingly recognized, however, that the agonist-bound GPCR can also form ternary complexes with other ligands or "accessory" proteins and display altered binding and/or signaling properties in relation to the binary agonist-receptor complex. Allosteric sites on GPCRs represent novel drug targets because allosteric modulators possess a number of theoretical advantages over classic orthosteric ligands, such as a ceiling level to the allosteric effect and a potential for greater GPCR subtype-selectivity. Because of the noncompetitive nature of allosteric phenomena, the detection and quantification of such effects often relies on a combination of equilibrium binding, nonequilibrium kinetic, and functional signaling assays. This review discusses the development and properties of allosteric receptor models for GPCRs and the detection and quantification of allosteric effects. Moreover, we provide an overview of the current knowledge regarding the location of possible allosteric sites on GPCRs and candidate endogenous allosteric modulators. Finally, we discuss the potential for allosteric effects arising from the formation of GPCR oligomers or GPCRs complexed with accessory cellular proteins. It is proposed that the study of allosteric phenomena will become of progressively greater import to the drug discovery process due to the advent of newer and more sensitive GPCR screening technologies.
G蛋白偶联受体(GPCRs)是细胞表面受体中最大的家族。这些受体是天然的变构蛋白,因为GPCRs的激动剂介导的信号传导需要受体蛋白在两个拓扑结构不同的结合位点之间传递构象变化,一个用于激动剂,另一个用于G蛋白。然而,现在越来越认识到,结合激动剂的GPCR也可以与其他配体或“辅助”蛋白形成三元复合物,并相对于二元激动剂-受体复合物表现出改变的结合和/或信号特性。GPCRs上的变构位点代表了新的药物靶点,因为变构调节剂相对于经典的正构配体具有许多理论优势,例如变构效应的上限水平和更高的GPCR亚型选择性潜力。由于变构现象的非竞争性本质,此类效应的检测和定量通常依赖于平衡结合、非平衡动力学和功能信号测定的组合。本综述讨论了GPCRs变构受体模型的发展和特性以及变构效应的检测和定量。此外,我们概述了关于GPCRs上可能的变构位点位置和候选内源性变构调节剂的当前知识。最后,我们讨论了由GPCR寡聚体或与辅助细胞蛋白复合的GPCR形成所产生的变构效应的潜力。有人提出,由于更新和更灵敏的GPCR筛选技术的出现,变构现象的研究将对药物发现过程变得越来越重要。